Tier 1 — highest

Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis

Chun-Wei Liang, Hsiao-Yi Cheng, Yu-Hao Lee, Chun-De Liao, Shih-Wei Huang
Osteoarthritis and Cartilage 2024 32(5):574–584

Bibliography

PubMed
PMID 38218227
DOI
10.1016/j.joca.2023.12.010
Funding
The authors reported that the research received no specific grant from public, commercial, or not-for-profit funding agencies.
Competing interests
The authors declared no competing interests.

Study snapshot

DesignSystematic review of RCTs through June 2023, RoB 2 and GRADE plus trial-sequential analysis
ModelAdults with osteoarthritis; mixed collagen interventions
Sample35 RCTs, 3,165 patients; main analysis 25 RCTs, 2,856 patients
InterventionCollagen derivatives including hydrolysed collagen and undenatured type II collagen vs controls
DurationMostly shorter than 6 months
EndpointsOsteoarthritis pain; Functional outcomes; Adverse events; Withdrawals

What the study showed, in plain terms

Pooled collagen-derivative trials showed small-to-moderate reductions in osteoarthritis pain and improvements in function without increased adverse-event rates.

Key findings

Pain SMD −0.35 (95% CI −0.48 to −0.22), function SMD −0.31 (−0.41 to −0.22); no increased adverse events.

What this study can and cannot tell us

Combines mechanistically distinct hydrolysed collagen and undenatured type II collagen; results cannot be attributed wholly to DoNotAge's bovine hydrolysate. Most trials under six months.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology